{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:17:23Z","timestamp":1791105443268,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2003,8,12]],"date-time":"2003-08-12T00:00:00Z","timestamp":1060646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2003,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Trastuzumab (Herceptin; Genentech, South San Francisco, CA) is a humanized anti\u2010ErbB\u20102 monoclonal antibody that has demonstrated antitumor function, especially in combination with other chemotherapies such as paclitaxel (Taxol; Bristol Myers\u2010Squibb, Princeton, NJ), in patients with tumors that overexpress ErbB\u20102. Because the repeated administration of low\u2010dose chemotherapy, such as paclitaxel, endorsed an antiangiogenic effect in vitro, and because trastuzumab was shown to inhibit angiogenesis in tumor xenografts, the authors investigated whether ErbB\u20102\u2010mediated angiogenic responses would be inhibited more effectively by the combined treatment of paclitaxel plus trastuzumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Tumor xenografts were established in 37 severe combined immunodeficiency mice by injecting the mammary fat pad with ErbB\u20102\u2010overexpressing human breast carcinoma cells. Mice then were treated with an immunoglobulin (IgG) control, trastuzumab, paclitaxel, or a combination treatment of trastuzumab plus paclitaxel. Tumorigenicity, lung metastasis, and tumor microvessel density (MVD) were evaluated. Vascular endothelial growth factor (VEGF) secretion, endothelial cell migration after treatment, and the status of phosphorylated Akt were evaluated in vitro to determine mechanisms underlying the inhibition of ErbB\u20102\u2010induced angiogenesis.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Mice treated with the trastuzumab plus paclitaxel combination exhibited significantly reduced mean tumor volumes compared with mice treated with the IgG control (419.5 mm<jats:sup>3<\/jats:sup> vs. 786.6 mm<jats:sup>3<\/jats:sup>, <jats:italic>P<\/jats:italic> &lt; 0.0001). Mice treated with trastuzumab had a mean tumor volume of 543.9 mm<jats:sup>3<\/jats:sup>, and mice treated with paclitaxel had a mean tumor volume of 574.9 mm<jats:sup>3<\/jats:sup>. Tumors from the trastuzumab\u2010plus\u2010paclitaxel group also had significantly decreased mean MVD compared with the control (30 \u00b1 8 MVD vs. 44 \u00b1 12 MVD, <jats:italic>P<\/jats:italic> &lt; 0.05). The trastuzumab group had tumors with a MVD of 35 \u00b1 7, similar to the paclitaxel\u2010treated group (35 \u00b1 9). Forty\u2010four percent of the mice in the trastuzumab\u2010plus\u2010paclitaxel group had metastases to the lungs compared with 50%, 63%, and 75% of the mice in the paclitaxel, trastuzumab, and control groups, respectively. In vitro, the ErbB\u20102\u2010overexpressing cells treated with combined trastuzumab plus paclitaxel secreted less VEGF than the cells treated with trastuzumab, paclitaxel, or control (185.9 pg\/mL vs. 233.2 pg\/mL, 261.3 pg\/mL, and 286.4 pg\/mL, respectively). In addition, the conditioned media from the combination group stimulated less mean endothelial cell migration (31.0 cells vs. 47.0 cells, 39.2 cells, and 67.5 cells, respectively). Furthermore, Akt phosphorylation contributed to VEGF up\u2010regulation and Akt phosphorylation was reduced more effectively by combined trastuzumab plus paclitaxel treatment compared with the other treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Combined trastuzumab plus paclitaxel treatment more effectively inhibited ErbB\u20102\u2010mediated angiogenesis than either treatment alone, which resulted in more pronounced tumoricidal effects. This effect may be mediated via the reduction of phosphorylated Akt. Cancer 2003;98:1377\u201385. \u00a9 2003 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.11656<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.11656","type":"journal-article","created":{"date-parts":[[2003,9,22]],"date-time":"2003-09-22T06:38:09Z","timestamp":1064212689000},"page":"1377-1385","source":"Crossref","is-referenced-by-count":81,"title":["Combined trastuzumab and paclitaxel treatment better inhibits ErbB\u20102\u2010mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone"],"prefix":"10.1002","volume":"98","author":[{"given":"Kristine S.","family":"Klos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangkyou","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianglin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dihua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,8,12]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/319230a0"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/319226a0"},{"key":"e_1_2_6_4_2","first-page":"1199","article-title":"Overexpression of the c\u2010erbB\u20102 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities","volume":"57","author":"Tan M","year":"1997","journal-title":"Cancer Res."},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3798106"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2470152"},{"key":"e_1_2_6_7_2","first-page":"4960","article-title":"Her\u20102\/neu expression in node\u2010negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease","volume":"53","author":"Press MF","year":"1993","journal-title":"Cancer Res."},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.8.2894"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1093"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197111182852108"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199101033240101"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.18.1.0287"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.21.12.3995-4004.2001"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E02-02-0084"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/416279b"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000055400"},{"issue":"4","key":"e_1_2_6_17_2","first-page":"78","article-title":"Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2\/neu\u2010overexpressing metastatic breast cancer","volume":"26","author":"Baselga J","year":"1999","journal-title":"Semin Oncol."},{"issue":"4","key":"e_1_2_6_18_2","first-page":"60","article-title":"Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)","volume":"26","author":"Sliwkowski MX","year":"1999","journal-title":"Semin Oncol."},{"key":"e_1_2_6_19_2","first-page":"427","article-title":"Antiangiogenic scheduling of lower dose cancer chemotherapy","volume":"7","author":"Gately S","year":"2001","journal-title":"Cancer J."},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00092-7"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf013"},{"key":"e_1_2_6_22_2","first-page":"6938","article-title":"Protracted low\u2010dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs","volume":"62","author":"Bocci G","year":"2002","journal-title":"Cancer Res."},{"issue":"2","key":"e_1_2_6_23_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000055401","article-title":"Interaction between Herceptin and taxanes","volume":"61","author":"Dieras V","year":"2001","journal-title":"Oncology."},{"issue":"6","key":"e_1_2_6_24_2","first-page":"21","article-title":"Trastuzumab and chemotherapeutics: drug interactions and synergies","volume":"27","author":"Pegram MD","year":"2000","journal-title":"Semin Oncol."},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(02)00510-5"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/36.4.641"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(96)00379-6"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.2000.00850.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.37263"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI5028"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI6127"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.040560897"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.11.8027"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/376599a0"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.20.9552"},{"key":"e_1_2_6_36_2","first-page":"847","article-title":"Paclitaxel induces programmed cell death in MDA\u2010MB\u2010468 human breast cancer cells","volume":"2","author":"McCloskey DE","year":"1996","journal-title":"Clin Cancer Res."},{"key":"e_1_2_6_37_2","first-page":"3620","article-title":"Mechanisms of taxol\u2010induced cell death are concentration dependent","volume":"58","author":"Torres K","year":"1998","journal-title":"Cancer Res."},{"key":"e_1_2_6_38_2","first-page":"1359","article-title":"Overexpression of c\u2010erbB\u20102\/neu in breast cancer cells confers increased resistance to taxol via mdr\u20101\u2010independent mechanisms","volume":"13","author":"Yu D","year":"1996","journal-title":"Oncogene."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.11656","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.11656","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:24:28Z","timestamp":1760297068000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.11656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8,12]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2003,10]]}},"alternative-id":["10.1002\/cncr.11656"],"URL":"https:\/\/doi.org\/10.1002\/cncr.11656","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,8,12]]}}}